Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Expression of RECK and matrix metalloproteinase-2 in ameloblastoma

Authors: Bin Zhang, Jin Zhang, Zhi-Ying Xu, Hong-Liang Xie

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Ameloblastoma is a frequent odontogenic benign tumor characterized by local invasiveness, high risk of recurrence and occasional metastasis and malignant transformation. Matrix metalloproteinase-2 (MMP-2) promotes tumor invasion and progression by destroying the extracellular matrix (ECM) and basement membrane. For this proteolytic activity, the endogenous inhibitor is reversion-inducing cysteine rich protein with Kazal motifs (RECK). The aim of this study was to characterize the relationship between RECK and MMP-2 expression and the clinical manifestation of ameloblastoma.

Methods

Immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) were employed to detect the protein and mRNA expression of RECK and MMP-2 in keratocystic odontogenic tumor (KCOT), ameloblastoma and ameloblastic carcinoma.

Results

RECK protein expression was significantly reduced in KCOT (87.5%), ameloblastoma (56.5%) and ameloblastic carcinoma (0%) (P < 0.01), and was significantly lower in recurrent ameloblastoma compared with primary ameloblastoma (P < 0.01), but did not differ by histological type of ameloblastoma. MMP-2 protein expression was significantly higher in ameloblastoma and ameloblastic carcinoma compared with KCOT (P < 0.01). RECK mRNA expression was significantly lower in ameloblastoma than in KCOT (P < 0.01), lower in recurrent ameloblastoma than in primary ameloblastoma, and was negative in ameloblastic carcinoma. MMP-2 mRNA expression was significantly higher in ameloblastoma compared with KCOT (P < 0.01), but was no different in recurrent ameloblastoma versus primary ameloblastoma. RECK protein expression was negatively associated with MMP-2 protein expression in ameloblastoma (r = -0.431, P < 0.01).

Conclusion

Low or no RECK expression and increased MMP-2 expression may be associated with negative clinical findings in ameloblastoma. RECK may participate in the invasion, recurrence and malignant transformation of ameloblastoma by regulating MMP-2 at the post-transcriptional level.
Appendix
Available only for authorised users
Literature
1.
Luo HY, Li TJ: Odontogenic tumors: A study of 1309 cases in a Chinese population. Oral Oncol. 2009, 45: 706-711. 10.1016/j.oraloncology.2008.11.001.CrossRefPubMed
2.
Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP: Ameloblastoma. Am J Clin Oncol. 2007, 30: 645-648. 10.1097/COC.0b013e3181573e59.CrossRefPubMed
3.
Kumamoto H, Yamauchi K, Yoshida M, Ooya K: Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med. 2003, 32: 114-120. 10.1034/j.1600-0714.2003.00086.x.CrossRefPubMed
4.
Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q, Wang J, Pan C: Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC cancer. 2008, 8: 182-10.1186/1471-2407-8-182.CrossRefPubMedPubMedCentral
5.
Zhang B, Zhang J, Huang HZ, Chen WL, Tao Q, Zeng DL, Zhang LT, Xu JH: Inhibition of ameloblastoma invasion in vitro and in vivo by inhibitor of metalloproteinase-2 activity. J Oral Pathol Med. 2009, 38: 731-736. 10.1111/j.1600-0714.2009.00771.x.CrossRefPubMed
6.
Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, Han I: RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007, 25: 696-702. 10.1002/jor.20323.CrossRefPubMed
7.
Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, Kami K, Mori T, Wada M, Noda M, Imamura M: RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res. 2003, 9: 1779-1784.PubMed
8.
Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M: The membrane-anchored MMP-inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001, 107: 789-800. 10.1016/S0092-8674(01)00597-9.CrossRefPubMed
9.
Eren B, Sar M, Oz B, Dincbas FH: MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. Ann Acad Med Singapore. 2008, 37: 32-39.PubMed
10.
Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP, Lin JT: Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer. 2007, 43: 799-808. 10.1016/j.ejca.2006.10.022.CrossRefPubMed
11.
Baum O, Hlushchuk R, Forster A, Greiner R, Clézardin P, Zhao Y, Djonov V, Gruber G: Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Int J Oncol. 2007, 30: 325-332.PubMed
12.
Pinheiro JJ, Freitas VM, Moretti AI, Jorge AG, Jaeger RG: Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathology. 2004, 45: 65-72. 10.1111/j.1365-2559.2004.01902.x.CrossRefPubMed
13.
Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, Mukogawa T, Matsumoto H, Kondo S, Takahashi C, Noda M, Nakajima Y: The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clinl Cancer Res. 2004, 10: 5572-5579. 10.1158/1078-0432.CCR-03-0656.CrossRef
14.
Mori T, Moriuchi R, Okazaki E, Yamada K, Katamine S: Tgat oncoprotein functions as a inhibitor of RECK by association of the unique C-terminal region. Biochem Biophys Res Commun. 2007, 355: 937-943. 10.1016/j.bbrc.2007.02.051.CrossRefPubMed
15.
Kumamoto H, Ooya K: Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med. 2006, 35: 345-351. 10.1111/j.1600-0714.2006.00432.x.CrossRefPubMed
16.
Wang Y, Xu HT, Ueda Y, Shimasaki M, Wang EH: Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours. Pathology. 2007, 39: 486-490. 10.1080/00313020701569964.CrossRefPubMed
17.
Shim KN, Jung SA, Joo YH, Yoo K: Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007, 42: 120-128. 10.1007/s00535-006-1975-y.CrossRefPubMed
18.
Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, Clark OH: Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer. 2006, 13: 1173-1783. 10.1677/erc.1.01226.CrossRefPubMedPubMedCentral
19.
Schwandner O, Schlamp A, Broll R, Bruch HP: Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis. 2007, 22: 127-136. 10.1007/s00384-006-0173-y.CrossRefPubMed
20.
Yoshida D, Nomura R, Teramoto A: Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK). J Neurooncol. 2008, 89: 141-150. 10.1007/s11060-008-9606-5.CrossRefPubMed
Metadata
Title
Expression of RECK and matrix metalloproteinase-2 in ameloblastoma
Authors
Bin Zhang
Jin Zhang
Zhi-Ying Xu
Hong-Liang Xie
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-427

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients

Research article

The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study

Research article

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

Research article

Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting

Research article

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

Research article

Signalling with retinoids in the human lung: validation of new tools for the expression study of retinoid receptors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits